MX340796B - Composiciones y procedimientos antigenicos del virus respiratorio sincitial. - Google Patents
Composiciones y procedimientos antigenicos del virus respiratorio sincitial.Info
- Publication number
- MX340796B MX340796B MX2012015030A MX2012015030A MX340796B MX 340796 B MX340796 B MX 340796B MX 2012015030 A MX2012015030 A MX 2012015030A MX 2012015030 A MX2012015030 A MX 2012015030A MX 340796 B MX340796 B MX 340796B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- respiratory syncytial
- syncytial virus
- antigenic compositions
- multilayer films
- Prior art date
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 230000005867 T cell response Effects 0.000 abstract 2
- 230000005875 antibody response Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36202910P | 2010-07-07 | 2010-07-07 | |
| US201161485669P | 2011-05-13 | 2011-05-13 | |
| PCT/US2011/043136 WO2012006395A1 (en) | 2010-07-07 | 2011-07-07 | Respiratory syncytial virus antigenic compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012015030A MX2012015030A (es) | 2013-06-13 |
| MX340796B true MX340796B (es) | 2016-07-27 |
Family
ID=45438747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012015030A MX340796B (es) | 2010-07-07 | 2011-07-07 | Composiciones y procedimientos antigenicos del virus respiratorio sincitial. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9487593B2 (enExample) |
| EP (1) | EP2590675B1 (enExample) |
| JP (1) | JP5890407B2 (enExample) |
| CN (2) | CN106008716B (enExample) |
| AU (1) | AU2011276251B2 (enExample) |
| BR (1) | BR112013000345B1 (enExample) |
| CA (1) | CA2799934C (enExample) |
| DK (1) | DK2590675T3 (enExample) |
| ES (1) | ES2688993T3 (enExample) |
| IL (1) | IL222723B (enExample) |
| MX (1) | MX340796B (enExample) |
| RU (1) | RU2609661C2 (enExample) |
| WO (1) | WO2012006395A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9433671B2 (en) | 2012-03-30 | 2016-09-06 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| US8883717B2 (en) | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
| SI2879702T1 (sl) | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| DK3033102T4 (da) | 2013-08-13 | 2024-02-26 | Univ Northwestern | Peptidkonjugerede partikler |
| JP6671300B2 (ja) | 2014-05-27 | 2020-03-25 | アーティフィシャル セル テクノロジーズ インコーポレイテッド | Ｔｆｆによる多層コーティング化コアの自動交互積層構築 |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| WO2017048689A1 (en) | 2015-09-16 | 2017-03-23 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| US20170230649A1 (en) * | 2016-02-05 | 2017-08-10 | Qualcomm Incorporated | Calibration of hybrid auto focus (af) imaging systems |
| EP3606942B1 (en) | 2017-04-04 | 2025-06-11 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| EP3694548A4 (en) * | 2017-10-13 | 2021-10-20 | Trellis Bioscience, LLC | CONFORMATIONAL EPITOPES IN THE CENTRAL PRESERVED REGION OF THE G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS |
| CN112088014B (zh) | 2018-02-28 | 2026-03-24 | 华盛顿大学 | 自组装纳米结构疫苗 |
| WO2020033742A1 (en) | 2018-08-08 | 2020-02-13 | Trellis Bioscience, Llc | Improved rsv passive and active vaccines |
| US20230414526A1 (en) * | 2022-03-29 | 2023-12-28 | Artificial Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9407182A (pt) * | 1993-08-06 | 1996-09-17 | Connaught Lab | Composição imunogênica processo de preparo de composição não-imunopotencializadora imunogênica processo para determinar a presença de anticorpos estojo para diagnóstico para determinar a presença de anticorpos e virus sincicial respiratório humano inativado purificado |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| ATE178906T1 (de) | 1994-08-25 | 1999-04-15 | Stichting Inst Dierhouderij | Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv- infektionen |
| FR2726471B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
| AUPO026596A0 (en) | 1996-06-05 | 1996-06-27 | Biomolecular Research Institute Limited | Viral peptide |
| EP1334119B2 (en) | 2000-10-18 | 2018-11-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Compositions and methods for modulating rsv infection and immunity |
| FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
| AUPR520201A0 (en) | 2001-05-23 | 2001-06-14 | Commonwealth Scientific And Industrial Research Organisation | Antiviral compounds |
| JP3997930B2 (ja) | 2003-02-27 | 2007-10-24 | 富士ゼロックス株式会社 | カーボンナノチューブの製造装置および製造方法 |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| US7615530B2 (en) | 2003-08-29 | 2009-11-10 | Artificial Cell Technologies, Inc. | Immunogenic compositions and methods of use |
| US7348399B2 (en) | 2003-08-29 | 2008-03-25 | Louisiana Tech University Foundation, Inc. | Nanofabricated polypeptide multilayer films, coatings, and microcapsules |
| EP1768993A4 (en) | 2004-06-16 | 2008-07-23 | Univ Johns Hopkins | CYSTIC REGION OF HUMAN RESPIRATORY SYNZYTIAL VIRUS AND METHOD OF USE THEREOF |
| US20080131450A1 (en) | 2004-07-23 | 2008-06-05 | Pierre Fabre Medicament | Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions |
| WO2006079928A2 (en) * | 2005-01-31 | 2006-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polyelectrolyte multilayer film, preparation and uses thereof |
| WO2006108226A1 (en) * | 2005-04-12 | 2006-10-19 | The University Of Queensland | Vaccine delivery system |
| CN101296945A (zh) * | 2005-10-25 | 2008-10-29 | 人工细胞技术公司 | 免疫原性组合物及其使用方法 |
| EP1972348A1 (en) | 2007-03-14 | 2008-09-24 | Pierre Fabre Medicament | Novel vaccine composition for the treatment of respiratory infectious diseases |
| EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
| US7723294B2 (en) * | 2007-04-02 | 2010-05-25 | Artificial Cell Technologies, Inc. | Polypeptide films and methods |
| US9095568B2 (en) * | 2007-09-26 | 2015-08-04 | Mark Berninger | Therapeutic and vaccine polyelectrolyte nanoparticle compositions |
| EP2058002A1 (en) * | 2007-10-31 | 2009-05-13 | Bestewil Holding B.V. | Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine |
| KR20110045008A (ko) | 2008-07-18 | 2011-05-03 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원 |
| WO2010075491A2 (en) | 2008-12-24 | 2010-07-01 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| US8846056B2 (en) | 2009-08-04 | 2014-09-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control | Anti-RSV immunogens and methods of immunization |
| US8883717B2 (en) * | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
-
2011
- 2011-07-07 CN CN201610369657.4A patent/CN106008716B/zh not_active Expired - Fee Related
- 2011-07-07 JP JP2013518819A patent/JP5890407B2/ja active Active
- 2011-07-07 AU AU2011276251A patent/AU2011276251B2/en not_active Ceased
- 2011-07-07 CA CA2799934A patent/CA2799934C/en active Active
- 2011-07-07 EP EP11731610.9A patent/EP2590675B1/en active Active
- 2011-07-07 WO PCT/US2011/043136 patent/WO2012006395A1/en not_active Ceased
- 2011-07-07 DK DK11731610.9T patent/DK2590675T3/en active
- 2011-07-07 ES ES11731610.9T patent/ES2688993T3/es active Active
- 2011-07-07 BR BR112013000345-6A patent/BR112013000345B1/pt not_active IP Right Cessation
- 2011-07-07 RU RU2013101972A patent/RU2609661C2/ru active
- 2011-07-07 CN CN201180033742.9A patent/CN103037898B/zh not_active Expired - Fee Related
- 2011-07-07 US US13/177,671 patent/US9487593B2/en active Active
- 2011-07-07 MX MX2012015030A patent/MX340796B/es active IP Right Grant
-
2012
- 2012-10-28 IL IL222723A patent/IL222723B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013535428A (ja) | 2013-09-12 |
| BR112013000345A2 (pt) | 2016-05-31 |
| EP2590675B1 (en) | 2018-08-29 |
| CN106008716A (zh) | 2016-10-12 |
| RU2013101972A (ru) | 2014-08-20 |
| CN106008716B (zh) | 2019-08-13 |
| AU2011276251A1 (en) | 2012-11-08 |
| US20120009254A1 (en) | 2012-01-12 |
| DK2590675T3 (en) | 2018-10-29 |
| EP2590675A1 (en) | 2013-05-15 |
| CA2799934A1 (en) | 2012-01-12 |
| CA2799934C (en) | 2020-01-28 |
| AU2011276251A2 (en) | 2013-01-24 |
| JP5890407B2 (ja) | 2016-03-22 |
| CN103037898A (zh) | 2013-04-10 |
| BR112013000345B1 (pt) | 2021-11-23 |
| IL222723A0 (en) | 2012-12-31 |
| AU2011276251B2 (en) | 2015-02-05 |
| IL222723B (en) | 2020-03-31 |
| MX2012015030A (es) | 2013-06-13 |
| CN103037898B (zh) | 2016-06-29 |
| ES2688993T3 (es) | 2018-11-07 |
| WO2012006395A1 (en) | 2012-01-12 |
| RU2609661C2 (ru) | 2017-02-02 |
| US9487593B2 (en) | 2016-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214962A1 (zh) | 流感病毒免疫原性组合物及其应用 | |
| WO2013006842A3 (en) | Self-replicating rna prime - protein boost vaccines | |
| MX2025009589A (es) | Vacunas a base de peptidos, metodos de fabricacion y sus usos para inducir una respuesta inmune | |
| WO2014136064A3 (en) | Immunogenic fusion polypeptides | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| BR112013000345A2 (pt) | composições antigênicas para vírus sincicial respiratório e métodos | |
| AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| EP4382164A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| WO2011032161A8 (en) | Vaccines directed to langerhans cells | |
| WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| WO2012051211A3 (en) | Antigen delivery platforms | |
| MX2017001638A (es) | Molecula portadora para antigenos. | |
| WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
| EP4056198A3 (en) | Outer membrane vesicles | |
| WO2008033966A3 (en) | Alphavirus replicon particles matched to protein antigens as immunological adjuvants | |
| WO2011156751A3 (en) | Immunogenic vaccine | |
| MX341775B (es) | Vectores para vacunas y metodos para potenciar respuestas inmunes. | |
| MX350707B (es) | Composiciones antigenas y procedimientos. | |
| WO2015179270A3 (en) | Combinatorial platform for the display of surface adjuvants and antigens | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| WO2015031778A3 (en) | Compositions and methods for the treatment or prevention of tuberculosis | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| MX350709B (es) | Composiciones y procedimientos antipaludismo. | |
| WO2015189698A3 (en) | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies | |
| WO2015149016A3 (en) | Breast and ovarian cancer vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |